Immunological features of alpha-synuclein in Parkinson's disease - PubMed (original) (raw)

Review

Immunological features of alpha-synuclein in Parkinson's disease

Cintia Roodveldt et al. J Cell Mol Med. 2008 Oct.

Erratum in

• J Cell Mol Med. 2008 Dec;12(6B):2875

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized pathologically by the presence, in the brain, of intra-cellular protein inclusions highly enriched in aggregated alpha-synuclein (alphaSyn), known as Lewy bodies. The onset of PD is accompanied by a local immune reaction in regions of the brain affected by the inclusions, although the mechanism that leads to pathogenesis is far from clear. It is, however, established that disease onset and progression are characterized by sustained activation of microglia, which is linked to significant dopaminergic neuron loss in the substantia nigra. A recent body of evidence indicates that aggregated or modified alphaSyn can indeed trigger the activation of microglia, inducing a lethal cascade of neuroinflammation and eventually, neuronal loss, pointing at aggregated and modified forms of alphaSyn as a primary cause of PD pathogenesis. By releasing toxic factors, or by phagocytosing neighbouring cells, activated microglia and astrocytes may form a self-perpetuating cycle for neuronal degeneration. Additional findings suggest a link between alphaSyn and humoural-mediated mechanisms in PD. In this review, we attempt to recapitulate our current understanding of PD physiopathology focused on alphaSyn and its links with the immune system, as well as of novel and promising therapeutic avenues for the treatment of PD and of other synucleinopathies.

PubMed Disclaimer

Similar articles

• Neuropathology of α-synuclein in Parkinson's disease.
  Choong CJ, Mochizuki H. Choong CJ, et al. Neuropathology. 2022 Apr;42(2):93-103. doi: 10.1111/neup.12812. Epub 2022 Mar 31. Neuropathology. 2022. PMID: 35362115 Review.
• Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
  Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Zhang W, et al. FASEB J. 2005 Apr;19(6):533-42. doi: 10.1096/fj.04-2751com. FASEB J. 2005. PMID: 15791003
• Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
  Ren WQ, Tian ZM, Yin F, Sun JZ, Zhang JN. Ren WQ, et al. Pharmazie. 2016 Feb;71(2):51-5. Pharmazie. 2016. PMID: 27004367
• The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
  Yasuda T, Mochizuki H. Yasuda T, et al. Apoptosis. 2010 Nov;15(11):1312-21. doi: 10.1007/s10495-010-0486-8. Apoptosis. 2010. PMID: 20221696 Review.
• Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.
  Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M. Codolo G, et al. PLoS One. 2013;8(1):e55375. doi: 10.1371/journal.pone.0055375. Epub 2013 Jan 31. PLoS One. 2013. PMID: 23383169 Free PMC article.

Cited by

• Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy.
  Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Hebron ML, et al. J Clin Cell Immunol. 2014 Sep 30;5:259. doi: 10.4172/2155-9899.1000259. J Clin Cell Immunol. 2014. PMID: 25635231 Free PMC article.
• Neuronal autophagy, α-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain.
  Plotegher N, Civiero L. Plotegher N, et al. J Neurosci. 2012 Oct 24;32(43):14851-3. doi: 10.1523/JNEUROSCI.3588-12.2012. J Neurosci. 2012. PMID: 23100407 Free PMC article. No abstract available.
• Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.
  Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ, Ceballos-Diaz C, Robertson J, Golde TE, Giasson BI. Sacino AN, et al. Acta Neuropathol. 2014 May;127(5):645-65. doi: 10.1007/s00401-014-1268-0. Acta Neuropathol. 2014. PMID: 24659240 Free PMC article.
• Microglial cell origin and phenotypes in health and disease.
  Saijo K, Glass CK. Saijo K, et al. Nat Rev Immunol. 2011 Oct 25;11(11):775-87. doi: 10.1038/nri3086. Nat Rev Immunol. 2011. PMID: 22025055 Review.
• Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies.
  Erskine D, Taylor JP, Thomas A, Collerton D, McKeith I, Khundakar A, Attems J, Morris C. Erskine D, et al. Neurosci Bull. 2019 Apr;35(2):295-300. doi: 10.1007/s12264-019-00341-4. Epub 2019 Feb 6. Neurosci Bull. 2019. PMID: 30729454 Free PMC article. No abstract available.

References

1. 1. Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions – report of a workshop. Mov Disord. 1998;13:759–67. - PubMed
2. 1. Mayeux R. Epidemiology of neurodegen-eration. Annu Rev Neurosci. 2003;26:81–104. - PubMed
3. 1. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 1987;45:19–34. - PubMed
4. 1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469–73. - PMC - PubMed
5. 1. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information